A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Atezolizumab (Primary) ; SAR-444200 (Primary)
- Indications Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
Most Recent Events
- 17 Jan 2025 Planned End Date changed from 12 Dec 2030 to 25 Dec 2025.
- 17 Jan 2025 Planned primary completion date changed from 12 Dec 2030 to 25 Dec 2025.
- 17 Jan 2025 Status changed from recruiting to active, no longer recruiting.